

(7) Replace Example 6 at page 27 with the following:

- - - Example 6

Identification of T-Cell Epitopes in a Protease Hybrid (GG36-BPN') (SEQ ID NO: 236)

After determining the location of a T-cell epitope, a protease hybrid was constructed using established protein engineering techniques. The hybrid was constructed so that a highly allergenic amino acid sequence of the protein was replaced with a corresponding sequence from a less allergenic homolog. In this instance, the first 122 amino acids of the protease were derived from GG36, and the remaining amino acid sequence was derived from BPN'.

The hybrid was first tested from a 100 ppm sample in North American condition in 24 well assay at .5 ppm, superfixed swatches, liquid (Tide KT) at .5 in 24 well assay with 3K swatches, and in the N'N'-dimethyl Casein Assay, 5 g/l DMC in NA detergent, TNBS detection method.

The results are shown in Figures 16 (SEQ ID NOS: 230 and 231), 17 (SEQ ID NOS: 232 through 235) and 18 (SEQ ID NO: 236).

IN THE CLAIMS:

Please replace claims 1 and 8 with the following clean copy of said amended claims. A marked-up version of said claims is appended hereto.

DJ A
1.(Once Amended) A variant of a polypeptide of interest comprising a T-cell epitope, wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that said variant produces an immunogenic response in an individual which is greater than the immunogenic response produced by said polypeptide of interest.

A 8
8.(Once amended) The variant of claim 1 wherein said T-cell epitope is altered by having a terminal portion of said polypeptide of interest comprising said T-cell epitope replaced with a corresponding terminal portion of a homolog of said polypeptide of interest wherein said homolog does not comprise a T-cell epitope identical to said replaced T-cell epitope.

Please add the following new claims

29. The variant of claim 1, wherein said polypeptide of interest is a therapeutic protein.
30. A variant of a polypeptide of interest comprising a T-cell epitope, wherein said variant differs from said polypeptide of interest by having a T-cell epitope that has been altered by amino acid substitutions such that said variant produces an immunogenic response in an individual which is greater than the immunogenic response produced by said polypeptide of interest.

Please cancel claims 2, 3 and 14 - 28.